Sanofi
Global healthcare company pursuing a dual AI strategy: an internally built generative-AI companion deployed to most of its workforce, alongside external AI drug-discovery collaborations.
- Company type
- Global healthcare company
- Headquarters
- Paris, France
- Website
- https://www.sanofi.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2026-03-23 — AI-driven biologics collaboration with Earendil Labs (co-backed with Pfizer) (Earendil Labs). Sanofi backed Earendil Labs' AI-driven biologics platform as part of a $787 million financing round co-backed with Pfizer, and separately pledged up to $1.72 billion in milestones for exclusive worldwide licenses to two bispecific antibodies for autoimmune and inflammatory bowel diseases. Disclosed: $787M round (co-backed with Pfizer); up to $1.72B in Sanofi milestones. Source: BioSpace (accessed 2026-07-29)
- 2024-10-01 — Internal generative-AI companion "Concierge" (build-not-buy) (Internal build (Snowflake + Elementum AI)). Rather than adopting a single external assistant, Sanofi built an internal generative-AI companion called Concierge (using Snowflake infrastructure and Elementum AI), which debuted in October 2024 and is reported to be used by roughly 60,000 employees — about 80% of Sanofi's workforce. No financial terms for the internal build were disclosed. Source: Fortune (accessed 2026-07-29)
- 2023-12-04 — Physics-based drug discovery collaboration with Aqemia (Aqemia). Sanofi entered a multi-year collaboration with Aqemia to apply its quantum-physics and generative-AI algorithms to small-molecule drug discovery. The deal was reported to be worth up to $140 million. Disclosed: Up to $140M (per reporting). Source: Fierce Biotech (accessed 2026-07-29)